Literature DB >> 18719867

[Local botulinum toxin A for treating chronic sialorrhea].

E Krause1, K Bötzel, R de la Chaux, R Gürkov.   

Abstract

BACKGROUND: Sialorrhea and drooling interfere with oral communication and nutrition, posing problems for hygiene, nursing, and social interactions. Therapeutic efforts such as swallowing therapy, systemic medications, operations, and irradiation are often insufficient or accompanied by side effects.
MATERIALS AND METHODS: Ten patients with therapy-resistant sialorrhea of various etiologies were treated between 2002 and 2007 with sonography-guided botulinum toxin A (BTA) injections into the parotid and submandibular glands bilaterally. Therapeutic success was evaluated using established symptom scores, and the glandular tissue size was sonographically measured before and 3 months after injections.
RESULTS: All 10 patients benefited from the BTA therapy, as shown by significant reduction of the troublesome sialorrhea. The effect lasted 6-28 weeks. On one occasion, transient xerostomia occurred. Sonographic measurements revealed no morphologic changes.
CONCLUSION: BTA is an effective and safe treatment for chronic sialorrhea. The effect is reversible. It causes no sonographically detectable changes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18719867     DOI: 10.1007/s00106-008-1820-0

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  19 in total

1.  Treatment of chronic parotid sialectasis with botulinum toxin A.

Authors:  Orlando Guntinas-Lichius; Markus Jungehülsing
Journal:  Laryngoscope       Date:  2002-03       Impact factor: 3.325

2.  A randomized trial of botulinum toxin A for treatment of drooling.

Authors:  A Lipp; T Trottenberg; T Schink; A Kupsch; G Arnold
Journal:  Neurology       Date:  2003-11-11       Impact factor: 9.910

Review 3.  Botulinum toxin in the management of sialorrhoea: a systematic review.

Authors:  M Lim; A Mace; S A Reza Nouraei; G Sandhu
Journal:  Clin Otolaryngol       Date:  2006-08       Impact factor: 2.597

4.  Botulinum toxin, a historical note.

Authors:  F J Erbguth
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

5.  Drool control: long-term follow-up.

Authors:  D Rapp
Journal:  Dev Med Child Neurol       Date:  1980-08       Impact factor: 5.449

6.  [Blocking secretion of exocrine glands in the head-neck area by administration of botulinum toxin A. Therapy of a rare disease picture].

Authors:  M Ellies; R Laskawi; S Rohrbach-Volland; R Rödel; W Beuche
Journal:  HNO       Date:  2001-10       Impact factor: 1.284

7.  Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment--botulinum toxin A injections of the parotid glands.

Authors:  K O Bushara
Journal:  Med Hypotheses       Date:  1997-04       Impact factor: 1.538

8.  Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.

Authors:  Giovanni Lagalla; Marzia Millevolte; Marianna Capecci; Leandro Provinciali; Maria Gabriella Ceravolo
Journal:  Mov Disord       Date:  2006-05       Impact factor: 10.338

9.  Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.

Authors:  Francesca Mancini; Roberta Zangaglia; Silvano Cristina; Maria Grazia Sommaruga; Emilia Martignoni; Giuseppe Nappi; Claudio Pacchetti
Journal:  Mov Disord       Date:  2003-06       Impact factor: 10.338

10.  Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy.

Authors:  Robert Savarese; Martin Diamond; Elie Elovic; Scott R Millis
Journal:  Am J Phys Med Rehabil       Date:  2004-04       Impact factor: 2.159

View more
  1 in total

1.  Patient benefit from treatment with botulinum neurotoxin A for functional indications in otorhinolaryngology.

Authors:  Thomas Braun; Robert Gürkov; John Martin Hempel; Alexander Berghaus; Eike Krause
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-06-19       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.